Piramal Pharma Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Piramal Pharma Ltd is up for a third straight session in a row. The stock is quoting at Rs 163.99, up 6.62% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.75% on the day, quoting at 24195.15. The Sensex is at 77763.49, down 0.96%. Piramal Pharma Ltd has added around 20.51% in last one month.

Meanwhile, Nifty Pharma index of which Piramal Pharma Ltd is a constituent, has added around 3.23% in last one month and is currently quoting at 22455.45, up 2.24% on the day. The volume in the stock stood at 422.04 lakh shares today, compared to the daily average of 30.77 lakh shares in last one month.

The benchmark April futures contract for the stock is quoting at Rs 162.77, up 6.78% on the day. Piramal Pharma Ltd is down 25.42% in last one year as compared to a 0.21% fall in NIFTY and a 4.48% fall in the Nifty Pharma index.

The PE of the stock is 27.73 based on TTM earnings ending December 25.

Piramal Pharma will hold a meeting of the Board of Directors of the Company on 28 April 2026.

Piramal Pharma Ltd rose for a third straight session today. The stock is quoting at Rs 149.59, up 2.13% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 1.57% on the day, quoting at 24216.6. The Sensex is at 78059.78, up 1.58%. Piramal Pharma Ltd has added around 7.84% in last one month.

Meanwhile, Nifty Pharma index of which Piramal Pharma Ltd is a constituent, has added around 0.88% in last one month and is currently quoting at 22100.1, up 1.13% on the day. The volume in the stock stood at 16.87 lakh shares today, compared to the daily average of 32.69 lakh shares in last one month.

The benchmark April futures contract for the stock is quoting at Rs 149.53, up 2.34% on the day. Piramal Pharma Ltd is down 32.57% in last one year as compared to a 3.33% gain in NIFTY and a 7.07% gain in the Nifty Pharma index.

The PE of the stock is 26.4 based on TTM earnings ending December 25.

In a regulatory filing made in December last year, the company said that the United States Food and Drug Administration (US FDA) conducted a general good manufacturing practices (GMP) inspection of Piramal Pharma?s Lexington (Kentucky, USA) facility from 03 December 2025 to 10 December 2025.

At the conclusion of the inspection, the US FDA issued a Form-483, with four observations.

These observations are related to enhancement in procedures and will be classified as a VAI (voluntary action indicated). The company is preparing a detailed response to the observations, which will be submitted to the US FDA within the stipulated timelines,? Piramal Pharma had said in a statement.

Offering updates on the same, Piramal Pharma today (13 April 2026) said that the US FDA has issued an establishment inspection report (EIR) for the said manufacturing facility with VAI (voluntary action indicated).

Receipt of said EIR marks successful closure of the inspection, the company stated.

Piramal Pharma offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries.

The company a consolidated net loss of Rs 136.19 crore in the quarter ended December 2025 as against net profit of Rs 3.68 crore during the previous quarter ended December 2024. Sales declined 2.92% to Rs 2,139.87 crore in Q3 FY26 as compared with Q3 FY25.

The scrip rose 0.68% to currently trade at Rs 147.10 on the BSE.